Patents by Inventor Amita Datta-Mannan

Amita Datta-Mannan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SUBCUTANEOUS ABSORPTION AND BIOAVAILABILITY OF ANTIBODIES
    Publication number: 20230236199
    Abstract: Provided herein are methods of selecting antibodies suitable for subcutaneous administration; methods of improving subcutaneous absorption and bioavailability of antibodies; and methods of administering an antibody to a subject subcutaneously.
    Type: Application
    Filed: April 16, 2021
    Publication date: July 27, 2023
    Inventors: Selina Alyssa Lynette Estwick, Amita Datta-Mannan
  • Parathyroid hormone-anti-RANKL antibody fusion compounds
    Patent number: 11492386
    Abstract: Fusion compounds and methods of using same are provided which bind and neutralize human receptor activator of nuclear factor kappa-B ligand and are agonistic to parathyroid hormone receptor 1 signaling, said compounds are useful as agents for bone healing or treating conditions associated with bone mass loss or degeneration including treating osteoporosis.
    Type: Grant
    Filed: January 25, 2017
    Date of Patent: November 8, 2022
    Assignee: ELI LILLY AND COMPANY
    Inventors: Andrew H Korytko, Yanfei L Ma, Amita Datta-Mannan, Victor H Obungu
  • GIP/GLP1 CO-AGONIST COMPOUNDS
    Publication number: 20220048967
    Abstract: The present invention relates to compounds having activity at both the human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The present invention also relates to compounds having an extended duration of action at each of these receptors. Furthermore, the present invention relates to compounds that may be administered orally. Compounds may be useful in the treatment of type 2 diabetes mellitus (“T2DM”). Also, the compounds may be useful in the treatment of obesity.
    Type: Application
    Filed: July 2, 2021
    Publication date: February 17, 2022
    Inventors: Milata Mary ABRAHAM, Jorge ALSINA-FERNANDEZ, Robert Andrew BROWN, Over CABRERA, Tamer COSKUN, Robert Chadwick CUMMINS, Mohamed ElSayed Hamed ELSAYED, Hongchang QU, James Lincoln WALLIS, Kyle Wynn SLOOP, Francis Stafford WILLARD, Thi Thanh Huyen TRAN, Aktham ABURUB, Phenil Jayantilal PATEL, Amita DATTA-MANNAN, Xianyin LAI
  • GIP/GLP1 co-agonist compounds
    Patent number: 11084861
    Abstract: The present invention relates to compounds having activity at both the human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The present invention also relates to compounds having an extended duration of action at each of these receptors. Furthermore, the present invention relates to compounds that may be administered orally. Compounds may be useful in the treatment of type 2 diabetes mellitus (“T2DM”). Also, the compounds may be useful in the treatment of obesity.
    Type: Grant
    Filed: July 22, 2019
    Date of Patent: August 10, 2021
    Assignee: Eli Lilly and Company
    Inventors: Milata Mary Abraham, Jorge Alsina-Fernandez, Robert Andrew Brown, Over Cabrera, Tamer Coskun, Robert Chadwick Cummins, Mohamed ElSayed Hamed Elsayed, Hongchang Qu, James Lincoln Wallis, Amita Datta-Mannan, Xianyin Lai
  • PARATHYROID HORMONE-ANTI-RANKL ANTIBODY FUSION COMPOUNDS
    Publication number: 20200354427
    Abstract: Fusion compounds and methods of using same are provided which bind and neutralize human receptor activator of nuclear factor kappa-B ligand and are agonistic to parathyroid hormone receptor 1 signaling, said compounds are useful as agents for bone healing or treating conditions associated with bone mass loss or degeneration including treating osteoporosis.
    Type: Application
    Filed: January 25, 2017
    Publication date: November 12, 2020
    Inventors: Andrew H Korytko, Yanfei L Ma, Amita Datta-Mannan, Victor H Obungu
  • GIP/GLP1 CO-AGONIST COMPOUNDS
    Publication number: 20200024322
    Abstract: The present invention relates to compounds having activity at both the human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The present invention also relates to compounds having an extended duration of action at each of these receptors. Furthermore, the present invention relates to compounds that may be administered orally. Compounds may be useful in the treatment of type 2 diabetes mellitus (“T2DM”). Also, the compounds may be useful in the treatment of obesity.
    Type: Application
    Filed: July 22, 2019
    Publication date: January 23, 2020
    Inventors: Milata Mary Abraham, Jorge Alsina-Fernandez, Robert Andrew Brown, Over Cabrera, Tamer Coskun, Robert Chadwick Cummins, Mohamed ElSayed Hamed Elsayed, Hongchang Qu, James Lincoln Wallis, Kyle Wynn Sloop, Francis Stafford Willard, Thi Thanh Huyen Tran, Aktham Aburub, Phenil Jayantilal Patel, Amita Datta-Mannan, Xianyin Lai